Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd. more
Time Frame | BLTE | Sector | S&P500 |
---|---|---|---|
1-Week Return | -1.86% | -2.06% | -0.55% |
1-Month Return | -23.92% | -1.92% | 2.72% |
3-Month Return | 30.32% | -10.4% | 7.66% |
6-Month Return | 26.81% | -4.6% | 10.15% |
1-Year Return | 40.35% | 4.06% | 27.53% |
3-Year Return | 494.52% | 1.94% | 32.31% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Cost of Revenue | 17.00K | 30.00K | 198.00K | 399.00K | [{"date":"2020-12-31","value":4.26,"profit":true},{"date":"2021-12-31","value":7.52,"profit":true},{"date":"2022-12-31","value":49.62,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Gross Profit | (17.00K) | (30.00K) | (198.00K) | (399.00K) | [{"date":"2020-12-31","value":-1700000,"profit":false},{"date":"2021-12-31","value":-3000000,"profit":false},{"date":"2022-12-31","value":-19800000,"profit":false},{"date":"2023-12-31","value":-39900000,"profit":false}] | |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] | |
Operating Expenses | 5.74M | 9.80M | 12.82M | 31.67M | [{"date":"2020-12-31","value":18.14,"profit":true},{"date":"2021-12-31","value":30.94,"profit":true},{"date":"2022-12-31","value":40.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Operating Income | (5.74M) | (9.80M) | (12.82M) | (31.67M) | [{"date":"2020-12-31","value":-574300000,"profit":false},{"date":"2021-12-31","value":-979700000,"profit":false},{"date":"2022-12-31","value":-1282100000,"profit":false},{"date":"2023-12-31","value":-3166800000,"profit":false}] | |
Total Non-Operating Income/Expense | (18.00K) | 136.00K | 180.00K | 94.00K | [{"date":"2020-12-31","value":-10,"profit":false},{"date":"2021-12-31","value":75.56,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":52.22,"profit":true}] | |
Pre-Tax Income | (5.75M) | (9.67M) | (12.65M) | (31.62M) | [{"date":"2020-12-31","value":-575200000,"profit":false},{"date":"2021-12-31","value":-966600000,"profit":false},{"date":"2022-12-31","value":-1264800000,"profit":false},{"date":"2023-12-31","value":-3162300000,"profit":false}] | |
Income Taxes | 1.00K | 126.00K | (173.00K) | 9.00K | [{"date":"2020-12-31","value":0.79,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-137.3,"profit":false},{"date":"2023-12-31","value":7.14,"profit":true}] | |
Income After Taxes | (5.75M) | (9.79M) | (12.47M) | (31.63M) | [{"date":"2020-12-31","value":-575300000,"profit":false},{"date":"2021-12-31","value":-979200000,"profit":false},{"date":"2022-12-31","value":-1247500000,"profit":false},{"date":"2023-12-31","value":-3163200000,"profit":false}] | |
Income From Continuous Operations | (5.75M) | (9.67M) | (12.65M) | (31.63M) | [{"date":"2020-12-31","value":-575300000,"profit":false},{"date":"2021-12-31","value":-966600000,"profit":false},{"date":"2022-12-31","value":-1264800000,"profit":false},{"date":"2023-12-31","value":-3163200000,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (5.75M) | (9.79M) | (12.47M) | (31.63M) | [{"date":"2020-12-31","value":-575300000,"profit":false},{"date":"2021-12-31","value":-979200000,"profit":false},{"date":"2022-12-31","value":-1247500000,"profit":false},{"date":"2023-12-31","value":-3163200000,"profit":false}] | |
EPS (Diluted) | - | (0.20) | (0.96) | (1.24) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-20,"profit":false},{"date":"2022-12-31","value":-96,"profit":false},{"date":"2023-12-31","value":-124,"profit":false}] | |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BLTE | |
---|---|
ROA (LTM) | -25.58% |
ROE (LTM) | -40.04% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BLTE | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.03 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.97 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BLTE | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 17.36 |
EV/R | 0.00 |
EV/Ebitda | NM |
Belite Bio Inc ADR (BLTE) share price today is $62.96
Yes, Indians can buy shares of Belite Bio Inc ADR (BLTE) on Vested. To buy Belite Bio Inc ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BLTE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Belite Bio Inc ADR (BLTE) via the Vested app. You can start investing in Belite Bio Inc ADR (BLTE) with a minimum investment of $1.
You can invest in shares of Belite Bio Inc ADR (BLTE) via Vested in three simple steps:
The 52-week high price of Belite Bio Inc ADR (BLTE) is $86.53. The 52-week low price of Belite Bio Inc ADR (BLTE) is $31.
The price-to-earnings (P/E) ratio of Belite Bio Inc ADR (BLTE) is
The price-to-book (P/B) ratio of Belite Bio Inc ADR (BLTE) is 17.36
The dividend yield of Belite Bio Inc ADR (BLTE) is 0.00%
The market capitalization of Belite Bio Inc ADR (BLTE) is $1.95B
The stock symbol (or ticker) of Belite Bio Inc ADR is BLTE